Evidence map›Paper›PMID 22696662›Full record

ArticleJournal of virology2012

Live-attenuated lentivirus immunization modulates innate immunity and inflammation while protecting rhesus macaques from vaginal simian immunodeficiency virus challenge.

Meritxell Genescà, Zhong-Min Ma, Yichuan Wang, Basel Assaf, Huma Qureshi, Linda Fritts, Ying Huang, Michael B McChesney, Christopher J Miller

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. New prospects for a preventive HIV-1 vaccine.Journal of virus eradication · 2015
    Article
  7. Review
  8. Article
  9. Article
  10. HIV-1 vaccines: challenges and new perspectives.Human vaccines & immunotherapeutics · 2014
    Review
  11. Nonhuman primate models for HIV/AIDS vaccine development.Current protocols in immunology · 2013
    Review
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Meritxell GenescàCenter for Comparative Medicine, University of California, Davis, California, USA.
Zhong-Min Ma
Yichuan Wang
Basel Assaf
Huma Qureshi
Linda Fritts
Ying Huang
Michael B McChesney
Christopher J Miller
University of California, Davis · USFred Hutch Cancer Center · US

Funding

ZONA PELLUCIDA PEPTIDES AS IMMUNOCONTRACEPTIVE ANTIGENSP51RR000169 · NCRR · UNIVERSITY OF CALIFORNIA DAVIS · PI HYDE, DALLAS MELVIN · 1985 to 2011
$126.2M
Supplement to Mechanisms of Protection in Live-attenuated AIDS VaccinesP01AI066314 · NIAID · UNIVERSITY OF CALIFORNIA DAVIS · PI MILLER, CHRISTOPHER JAMES · 2005 to 2009
$8.5M
PROTECTIVE MECHANISMS WITH ATTENUATED LENTIVIRAL VACCINER01AI044480 · NIAID · UNIVERSITY OF CALIFORNIA DAVIS · PI MILLER, CHRISTOPHER · 1998 to 2002
$2.5M
NCRR NIH HHS P51 RR000169NCRR NIH HHS RR00169NIAID NIH HHS AI066314NIAID NIH HHS AI44480NIAID NIH HHS P01 AI066314
6 · The paper itself

Abstract

Immunization with attenuated lentiviruses is the only reliable method of protecting rhesus macaques (RM) from vaginal challenge with pathogenic simian immunodeficiency virus (SIV). CD8(+) lymphocyte depletion prior to SIVmac239 vaginal challenge demonstrated that a modest, Gag-specific CD8(+) T cell response induced by immunization with simian-human immunodeficiency virus 89.6 (SHIV89.6) protects RM. Although CD8(+) T cells are required for protection, there is no anamnestic expansion of SIV-specific CD8(+) T cells in any tissues except the vagina after challenge. Further, SHIV immunization increased the number of viral target cells in the vagina and cervix, suggesting that the ratio of target cells to antiviral CD8(+) T cells was not a determinant of protection. We hypothesized that persistent replication of the attenuated vaccine virus modulates inflammatory responses and limits T cell activation and expansion by inducing immunoregulatory T cell populations. We found that attenuated SHIV infection decreased the number of circulating plasmacytoid dendritic cells, suppressed T cell activation, decreased mRNA levels of proinflammatory mediators, and increased mRNA levels of immunoregulatory molecules. Three days after SIV vaginal challenge, SHIV-immunized RM had significantly more T regulatory cells in the vagina than the unimmunized RM. By day 14 postchallenge, immune activation and inflammation were characteristic of unimmunized RM but were minimal in SHIV-immunized RM. Thus, a modest vaccine-induced CD8(+) T cell response in the context of immunoregulatory suppression of T cell activation may protect against vaginal HIV transmission.

Indexed as

AIDS VaccinesAnimalsCD8-Positive T-LymphocytesFemaleHIV-1HIV InfectionsHumansImmunity, InnateImmunizationMacaca mulattaSAIDS VaccinesSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusVaccines, AttenuatedVaginaAIDS VaccinesSAIDS VaccinesVaccines, Attenuated

Identifiers

PMID22696662
PMCPMC3416105
OpenAlexW2038735489

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.